Evolving Standards in EGFR-Mutated Non–Small Cell Lung Cancer

Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss how data help shape first-line treatment decisions in EGFR-mutated non–small cell lung cancer.

Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss second-line treatment approaches and sequencing considerations in EGFR-mutated non–small cell lung cancer.

Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss factors that drive treatment and sequencing planning in EGFR-mutated non–small cell lung cancer.

Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss how the FDA approval of a subcutaneous formulation of amivantamab will affect clinical practice

Christine Lovly, MD, PhD, and Matthew Lee, MD, detail implementation and safety considerations for subcutaneous amivantamab in EGFR-mutated NSCLC.

Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss ongoing research to watch in EGFR-mutated non–small cell lung cancer